PDF(Pubmed)
Abstract：
Glioblastoma (GBM) causes nearly universal mortality as a result of the failure of conventional therapies including surgical resection, targeted radiation therapy, and chemotherapy. An increasingly important treatment option is combining immunotherapy with other therapies in both preclinical and clinical studies. The central nervous system (CNS) has been historically considered an immune privileged area, but increasing evidence, including the recent rediscovery of meningeal lymphatic vessels (MLVs), has overturned this notion. MLVs are populated by multiple immune cells and connect the CNS to the periphery by draining cerebrospinal fluid with soluble CNS antigens and immune cells into cervical lymph nodes. In the past few years, more and more studies have indicated that MLVs are involved in the regulation of inflammation and the immune response in the pathogenesis of various CNS diseases including GBM. Here, we explore the critical interlinkages between MLVs and GBM therapies including chemotherapy, radiotherapy and immunotherapy, and propose the meningeal lymphatic vasculature as a general target for GBM therapy.
摘要：
胶质母细胞瘤（GBM）由于包括手术切除在内的常规治疗失败而导致几乎普遍死亡。靶向放射治疗,和化疗。越来越重要的治疗选择是在临床前和临床研究中将免疫疗法与其他疗法相结合。中枢神经系统（CNS）历来被认为是免疫特权区，但越来越多的证据,包括最近重新发现的脑膜淋巴管（MLV），推翻了这个概念。MLV由多种免疫细胞填充，并通过将具有可溶性CNS抗原和免疫细胞的脑脊液排入颈部淋巴结来将CNS连接到外周。在过去的几年里,越来越多的研究表明,MLV在包括GBM在内的各种CNS疾病的发病过程中参与炎症和免疫应答的调节。这里,我们探索MLV和GBM治疗包括化疗之间的关键联系，放疗和免疫疗法，并提出脑膜淋巴管系统作为GBM治疗的一般目标。
